{"id":31163,"date":"2023-12-22T13:45:46","date_gmt":"2023-12-22T18:45:46","guid":{"rendered":"https:\/\/joinastudy.ca\/?p=31163"},"modified":"2023-12-22T13:47:30","modified_gmt":"2023-12-22T18:47:30","slug":"study-results-merck-reveal-new-pneumococcal-vaccine","status":"publish","type":"post","link":"https:\/\/joinastudy.ca\/fr\/study-results-merck-reveal-new-pneumococcal-vaccine\/","title":{"rendered":"Study Results \u2013 Merck Reveal New Pneumococcal Vaccine"},"content":{"rendered":"<p><b><span data-contrast=\"auto\">Merck &amp; Co.<\/span><\/b><span data-contrast=\"auto\"> has presented data from a phase 3 trial showcasing the potential of its pneumococcal vaccine candidate, V116, to rival Pfizer&rsquo;s current market dominance in vaccines of this nature. In the United States, Prevnar 20 (Pfizer\u2019s vaccine) currently commands a dominant 95% share. However, Merck contends that V116 offers broader protection, making it a strong competitor.<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559739&quot;:160,&quot;335559740&quot;:259}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">JoinAStudy investigator <\/span><a href=\"https:\/\/joinastudy.ca\/study-locations\/london-east-medical-centre-dr-dzongowski\/\"><b><span data-contrast=\"none\">Dr. Peter Dzongowski<\/span><\/b><\/a><span data-contrast=\"auto\"> was involved in this series of trials, and we would like to extend a massive thank you to him and his clinic patients. They have played an important role in collecting the data that is critical in Merck\u2019s ability to reach this conclusion.<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;201341983&quot;:0,&quot;335551550&quot;:1,&quot;335551620&quot;:1,&quot;335559685&quot;:0,&quot;335559737&quot;:0,&quot;335559738&quot;:0,&quot;335559739&quot;:160,&quot;335559740&quot;:259}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">In a phase 3 trial involving adults aged 50 and older, V116 showed just as good of an immune response as Prevnar 20 for all 10 common strains. Additionally, V116 showed superior immune responses for 10 out of its 11 common strains, a marked advantage over Prevnar 20. Notably, eight of V116&rsquo;s covered strains have no existing vaccines for protection, comprising around 30% of invasive pneumococcal disease (IPD) in individuals aged 65 and above.<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559739&quot;:160,&quot;335559740&quot;:259}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">While V116 covers one strain more than Prevnar 20, Merck emphasizes that this translates to approximately 30% more protection against IPD. Even when compared to other candidates in development by competitors like GSK (Vaxcyte, and Affinivax), Merck asserts that V116 provides superior coverage, aiming for an 85% protection rate versus 60% for other vaccines in development.<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559739&quot;:160,&quot;335559740&quot;:259}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">The broader strategy behind V116 is part of Merck&rsquo;s initiative to introduce a \u00ab\u00a0precision medicine mindset\u00a0\u00bb to vaccines. Dean Li, President of Merck Research Laboratories, highlighted V116 and its approved pediatric counterpart, Vaxneuvance, as key components of this strategy. The goal is to deliver vaccines that target the right strains at the appropriate stage of life, challenging existing perceptions and driving a shift in thinking around pneumococcal vaccination.<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559739&quot;:160,&quot;335559740&quot;:259}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">As Merck prepares to file for global approvals, these promising trial results position V116 as a formidable contender in the pneumococcal vaccine market, potentially disrupting Pfizer&rsquo;s long-standing dominance with Prevnar 20.<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559739&quot;:160,&quot;335559740&quot;:259}\">\u00a0<\/span><\/p>\n<p>&nbsp;<\/p>\n<p><span data-contrast=\"auto\">To read a more technical breakdown of this story, please click <\/span><a href=\"https:\/\/www.fiercebiotech.com\/biotech\/merck-co-strides-pfizers-turf-posting-pivotal-vaccine-data-and-heading-regulators\"><b><span data-contrast=\"none\">here<\/span><\/b><\/a><span data-contrast=\"auto\">.<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559739&quot;:160,&quot;335559740&quot;:259}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">For the official press release covering this news, click <\/span><a href=\"https:\/\/www.businesswire.com\/news\/home\/20231128147291\/en\/Merck%E2%80%99s-V116-an-Investigational-21-valent-Pneumococcal-Conjugate-Vaccine-Specifically-Designed-to-Protect-Adults-Demonstrated-Superior-Immunogenicity-for-10-of-11-Unique-Serotypes-Compared-to-PCV20-in-Adults-50-Years-of-Age-and-Older\"><b><span data-contrast=\"none\">here<\/span><\/b><\/a><span data-contrast=\"auto\">.\u00a0<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559739&quot;:160,&quot;335559740&quot;:259}\">\u00a0<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck &amp; Co. has presented data from a phase 3 trial showcasing the potential of its pneumococcal vaccine candidate, V116, to rival Pfizer&rsquo;s current market dominance in vaccines of this nature. In the United States, Prevnar 20 (Pfizer\u2019s vaccine) currently commands a dominant 95% share. However, Merck contends that V116 offers broader protection, making it<\/p>\n","protected":false},"author":964,"featured_media":31165,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[487,489,513,550],"tags":[],"class_list":["post-31163","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-drug-development","category-industry-news","category-health-and-wellness","category-study-results","category-487","category-489","category-513","category-550","description-off"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Study Results \u2013 Merck Reveal New Pneumococcal Vaccine - JoinAStudy.ca<\/title>\n<meta name=\"description\" content=\"Merck &amp; Co. has presented data from a phase 3 trial showcasing the potential of its pneumococcal vaccine candidate, V116.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/joinastudy.ca\/fr\/study-results-merck-reveal-new-pneumococcal-vaccine\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Study Results \u2013 Merck Reveal New Pneumococcal Vaccine\" \/>\n<meta property=\"og:description\" content=\"Merck &amp; Co. has presented data from a phase 3 trial showcasing the potential of its pneumococcal vaccine candidate, V116.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/joinastudy.ca\/fr\/study-results-merck-reveal-new-pneumococcal-vaccine\/\" \/>\n<meta property=\"og:site_name\" content=\"JoinAStudy.ca\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/joinastudy.ca\" \/>\n<meta property=\"article:published_time\" content=\"2023-12-22T18:45:46+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-12-22T18:47:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/joinastudy.ca\/wp-content\/uploads\/50782882936_924e5a7235_b.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"683\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"JoinAStudy Team\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@JoinAStudy_ca\" \/>\n<meta name=\"twitter:site\" content=\"@JoinAStudy_ca\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"JoinAStudy Team\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/joinastudy.ca\\\/fr\\\/study-results-merck-reveal-new-pneumococcal-vaccine\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/joinastudy.ca\\\/fr\\\/study-results-merck-reveal-new-pneumococcal-vaccine\\\/\"},\"author\":{\"name\":\"JoinAStudy Team\",\"@id\":\"https:\\\/\\\/joinastudy.ca\\\/fr\\\/#\\\/schema\\\/person\\\/da824a10716e724d72676ec94d865d71\"},\"headline\":\"Study Results \u2013 Merck Reveal New Pneumococcal Vaccine\",\"datePublished\":\"2023-12-22T18:45:46+00:00\",\"dateModified\":\"2023-12-22T18:47:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/joinastudy.ca\\\/fr\\\/study-results-merck-reveal-new-pneumococcal-vaccine\\\/\"},\"wordCount\":354,\"publisher\":{\"@id\":\"https:\\\/\\\/joinastudy.ca\\\/fr\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/joinastudy.ca\\\/fr\\\/study-results-merck-reveal-new-pneumococcal-vaccine\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/joinastudy.ca\\\/wp-content\\\/uploads\\\/50782882936_924e5a7235_b.jpg\",\"articleSection\":[\"Drug Development\",\"Industry News\",\"Health and Wellness\",\"Study Results\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/joinastudy.ca\\\/fr\\\/study-results-merck-reveal-new-pneumococcal-vaccine\\\/\",\"url\":\"https:\\\/\\\/joinastudy.ca\\\/fr\\\/study-results-merck-reveal-new-pneumococcal-vaccine\\\/\",\"name\":\"Study Results \u2013 Merck Reveal New Pneumococcal Vaccine - JoinAStudy.ca\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/joinastudy.ca\\\/fr\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/joinastudy.ca\\\/fr\\\/study-results-merck-reveal-new-pneumococcal-vaccine\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/joinastudy.ca\\\/fr\\\/study-results-merck-reveal-new-pneumococcal-vaccine\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/joinastudy.ca\\\/wp-content\\\/uploads\\\/50782882936_924e5a7235_b.jpg\",\"datePublished\":\"2023-12-22T18:45:46+00:00\",\"dateModified\":\"2023-12-22T18:47:30+00:00\",\"description\":\"Merck & Co. has presented data from a phase 3 trial showcasing the potential of its pneumococcal vaccine candidate, V116.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/joinastudy.ca\\\/fr\\\/study-results-merck-reveal-new-pneumococcal-vaccine\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/joinastudy.ca\\\/fr\\\/study-results-merck-reveal-new-pneumococcal-vaccine\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/joinastudy.ca\\\/fr\\\/study-results-merck-reveal-new-pneumococcal-vaccine\\\/#primaryimage\",\"url\":\"https:\\\/\\\/joinastudy.ca\\\/wp-content\\\/uploads\\\/50782882936_924e5a7235_b.jpg\",\"contentUrl\":\"https:\\\/\\\/joinastudy.ca\\\/wp-content\\\/uploads\\\/50782882936_924e5a7235_b.jpg\",\"width\":1024,\"height\":683,\"caption\":\"vaccine. Merck, Respiratory Syncytial Virus (RSV)\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/joinastudy.ca\\\/fr\\\/study-results-merck-reveal-new-pneumococcal-vaccine\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/joinastudy.ca\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Study Results \u2013 Merck Reveal New Pneumococcal Vaccine\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/joinastudy.ca\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/joinastudy.ca\\\/fr\\\/\",\"name\":\"JoinAStudy.ca\",\"description\":\"JoinAStudy.ca - Help create a healthier future\",\"publisher\":{\"@id\":\"https:\\\/\\\/joinastudy.ca\\\/fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/joinastudy.ca\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/joinastudy.ca\\\/fr\\\/#organization\",\"name\":\"JoinAStudy.ca\",\"url\":\"https:\\\/\\\/joinastudy.ca\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/joinastudy.ca\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/joinastudy.ca\\\/wp-content\\\/uploads\\\/JoinaStudy-Logo-Mobile-e1520526932796.png\",\"contentUrl\":\"https:\\\/\\\/joinastudy.ca\\\/wp-content\\\/uploads\\\/JoinaStudy-Logo-Mobile-e1520526932796.png\",\"width\":118,\"height\":65,\"caption\":\"JoinAStudy.ca\"},\"image\":{\"@id\":\"https:\\\/\\\/joinastudy.ca\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/joinastudy.ca\",\"https:\\\/\\\/x.com\\\/JoinAStudy_ca\",\"https:\\\/\\\/www.youtube.com\\\/channel\\\/UC_ed0XmzH5ImSNOEJcdXKqg\"],\"publishingPrinciples\":\"https:\\\/\\\/joinastudy.ca\\\/why-join-a-study\\\/\",\"ownershipFundingInfo\":\"https:\\\/\\\/joinastudy.ca\\\/information-disclaimer\\\/\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/joinastudy.ca\\\/fr\\\/#\\\/schema\\\/person\\\/da824a10716e724d72676ec94d865d71\",\"name\":\"JoinAStudy Team\",\"url\":\"https:\\\/\\\/joinastudy.ca\\\/fr\\\/author\\\/grant\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Study Results \u2013 Merck Reveal New Pneumococcal Vaccine - JoinAStudy.ca","description":"Merck & Co. has presented data from a phase 3 trial showcasing the potential of its pneumococcal vaccine candidate, V116.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/joinastudy.ca\/fr\/study-results-merck-reveal-new-pneumococcal-vaccine\/","og_locale":"fr_FR","og_type":"article","og_title":"Study Results \u2013 Merck Reveal New Pneumococcal Vaccine","og_description":"Merck & Co. has presented data from a phase 3 trial showcasing the potential of its pneumococcal vaccine candidate, V116.","og_url":"https:\/\/joinastudy.ca\/fr\/study-results-merck-reveal-new-pneumococcal-vaccine\/","og_site_name":"JoinAStudy.ca","article_publisher":"https:\/\/www.facebook.com\/joinastudy.ca","article_published_time":"2023-12-22T18:45:46+00:00","article_modified_time":"2023-12-22T18:47:30+00:00","og_image":[{"width":1024,"height":683,"url":"https:\/\/joinastudy.ca\/wp-content\/uploads\/50782882936_924e5a7235_b.jpg","type":"image\/jpeg"}],"author":"JoinAStudy Team","twitter_card":"summary_large_image","twitter_creator":"@JoinAStudy_ca","twitter_site":"@JoinAStudy_ca","twitter_misc":{"\u00c9crit par":"JoinAStudy Team","Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/joinastudy.ca\/fr\/study-results-merck-reveal-new-pneumococcal-vaccine\/#article","isPartOf":{"@id":"https:\/\/joinastudy.ca\/fr\/study-results-merck-reveal-new-pneumococcal-vaccine\/"},"author":{"name":"JoinAStudy Team","@id":"https:\/\/joinastudy.ca\/fr\/#\/schema\/person\/da824a10716e724d72676ec94d865d71"},"headline":"Study Results \u2013 Merck Reveal New Pneumococcal Vaccine","datePublished":"2023-12-22T18:45:46+00:00","dateModified":"2023-12-22T18:47:30+00:00","mainEntityOfPage":{"@id":"https:\/\/joinastudy.ca\/fr\/study-results-merck-reveal-new-pneumococcal-vaccine\/"},"wordCount":354,"publisher":{"@id":"https:\/\/joinastudy.ca\/fr\/#organization"},"image":{"@id":"https:\/\/joinastudy.ca\/fr\/study-results-merck-reveal-new-pneumococcal-vaccine\/#primaryimage"},"thumbnailUrl":"https:\/\/joinastudy.ca\/wp-content\/uploads\/50782882936_924e5a7235_b.jpg","articleSection":["Drug Development","Industry News","Health and Wellness","Study Results"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/joinastudy.ca\/fr\/study-results-merck-reveal-new-pneumococcal-vaccine\/","url":"https:\/\/joinastudy.ca\/fr\/study-results-merck-reveal-new-pneumococcal-vaccine\/","name":"Study Results \u2013 Merck Reveal New Pneumococcal Vaccine - JoinAStudy.ca","isPartOf":{"@id":"https:\/\/joinastudy.ca\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/joinastudy.ca\/fr\/study-results-merck-reveal-new-pneumococcal-vaccine\/#primaryimage"},"image":{"@id":"https:\/\/joinastudy.ca\/fr\/study-results-merck-reveal-new-pneumococcal-vaccine\/#primaryimage"},"thumbnailUrl":"https:\/\/joinastudy.ca\/wp-content\/uploads\/50782882936_924e5a7235_b.jpg","datePublished":"2023-12-22T18:45:46+00:00","dateModified":"2023-12-22T18:47:30+00:00","description":"Merck & Co. has presented data from a phase 3 trial showcasing the potential of its pneumococcal vaccine candidate, V116.","breadcrumb":{"@id":"https:\/\/joinastudy.ca\/fr\/study-results-merck-reveal-new-pneumococcal-vaccine\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/joinastudy.ca\/fr\/study-results-merck-reveal-new-pneumococcal-vaccine\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/joinastudy.ca\/fr\/study-results-merck-reveal-new-pneumococcal-vaccine\/#primaryimage","url":"https:\/\/joinastudy.ca\/wp-content\/uploads\/50782882936_924e5a7235_b.jpg","contentUrl":"https:\/\/joinastudy.ca\/wp-content\/uploads\/50782882936_924e5a7235_b.jpg","width":1024,"height":683,"caption":"vaccine. Merck, Respiratory Syncytial Virus (RSV)"},{"@type":"BreadcrumbList","@id":"https:\/\/joinastudy.ca\/fr\/study-results-merck-reveal-new-pneumococcal-vaccine\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/joinastudy.ca\/fr\/"},{"@type":"ListItem","position":2,"name":"Study Results \u2013 Merck Reveal New Pneumococcal Vaccine"}]},{"@type":"WebSite","@id":"https:\/\/joinastudy.ca\/fr\/#website","url":"https:\/\/joinastudy.ca\/fr\/","name":"JoinAStudy.ca","description":"JoinAStudy.ca - Help create a healthier future","publisher":{"@id":"https:\/\/joinastudy.ca\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/joinastudy.ca\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/joinastudy.ca\/fr\/#organization","name":"JoinAStudy.ca","url":"https:\/\/joinastudy.ca\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/joinastudy.ca\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/joinastudy.ca\/wp-content\/uploads\/JoinaStudy-Logo-Mobile-e1520526932796.png","contentUrl":"https:\/\/joinastudy.ca\/wp-content\/uploads\/JoinaStudy-Logo-Mobile-e1520526932796.png","width":118,"height":65,"caption":"JoinAStudy.ca"},"image":{"@id":"https:\/\/joinastudy.ca\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/joinastudy.ca","https:\/\/x.com\/JoinAStudy_ca","https:\/\/www.youtube.com\/channel\/UC_ed0XmzH5ImSNOEJcdXKqg"],"publishingPrinciples":"https:\/\/joinastudy.ca\/why-join-a-study\/","ownershipFundingInfo":"https:\/\/joinastudy.ca\/information-disclaimer\/"},{"@type":"Person","@id":"https:\/\/joinastudy.ca\/fr\/#\/schema\/person\/da824a10716e724d72676ec94d865d71","name":"JoinAStudy Team","url":"https:\/\/joinastudy.ca\/fr\/author\/grant\/"}]}},"_links":{"self":[{"href":"https:\/\/joinastudy.ca\/fr\/wp-json\/wp\/v2\/posts\/31163","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/joinastudy.ca\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/joinastudy.ca\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/joinastudy.ca\/fr\/wp-json\/wp\/v2\/users\/964"}],"replies":[{"embeddable":true,"href":"https:\/\/joinastudy.ca\/fr\/wp-json\/wp\/v2\/comments?post=31163"}],"version-history":[{"count":0,"href":"https:\/\/joinastudy.ca\/fr\/wp-json\/wp\/v2\/posts\/31163\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/joinastudy.ca\/fr\/wp-json\/wp\/v2\/media\/31165"}],"wp:attachment":[{"href":"https:\/\/joinastudy.ca\/fr\/wp-json\/wp\/v2\/media?parent=31163"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/joinastudy.ca\/fr\/wp-json\/wp\/v2\/categories?post=31163"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/joinastudy.ca\/fr\/wp-json\/wp\/v2\/tags?post=31163"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}